Allan S G, Farquhar D F, Harrison D J, Leonard R C
Cancer Chemother Pharmacol. 1986;18(1):86-7. doi: 10.1007/BF00253072.
A single blind randomised trial of two different anti-emetic regimens (A and B) was performed in 26 patients with breast carcinoma undergoing emetic i.v. cytotoxic chemotherapy. They all received oral Motival (nortriptylene/fluphenazine) for 48 h after therapy and for regimen A received N-saline i.v. with their cytotoxics whilst for regimen B patients were given 16 mg dexamethasone i.v. Patients were given the alternative regimen at the subsequent course of treatment. They were asked to assess overall nausea and number of vomiting episodes in the 24 h following therapy. There was a statistically significant reduction in both for the regimen containing dexamethasone. This agent causes few side effects and is particularly suited for out-patient use.
对26例接受致吐性静脉细胞毒性化疗的乳腺癌患者进行了一项关于两种不同止吐方案（A和B）的单盲随机试验。他们在治疗后均口服Motival（去甲替林/氟奋乃静）48小时，方案A在接受细胞毒性药物治疗时静脉输注生理盐水，而方案B的患者静脉注射16毫克地塞米松。患者在后续治疗过程中接受另一种方案。要求他们评估治疗后24小时内的总体恶心程度和呕吐发作次数。含地塞米松的方案在这两方面均有统计学上的显著降低。该药物副作用少，特别适合门诊使用。
